Integrated Bioinformatics Analysis of PALB2 Reveals Expression Patterns, Molecular Interactions, and Prognostic Significance in Breast Cancer

Abstract

BackgroundPartner and Localizer of BRCA2 (PALB2) is a key tumor suppressor gene involved in homologous recombination-mediated DNA repair through its interactions with BRCA1 and BRCA2. Germline alterations in PALB2 have been associated with hereditary breast cancer risk; however, its broader molecular role in breast cancer progression and prognosis requires further investigation. MethodsA comprehensive in-silico analysis of PALB2 was performed using publicly available databases and bioinformatics platforms. Differential expression of PALB2 in breast cancer were evaluated using GEPIA2. Prognostic significance was assessed through Kaplan-Meier analyses for overall survival (OS) and disease-free survival (DFS). Protein-protein interaction (PPI) networks were constructed using STRING. Functional enrichment analyses of PALB2-associated genes were conducted using g. Mutational profiling of PALB2 in breast cancer was performed using cBioPortal with data from TCGA breast cancer cohorts. ResultsPALB2 expression was elevated in breast tumor tissues compared with normal breast tissues. Survival analyses revealed no statistically significant association between PALB2 expression and either overall survival (HR = 0.88, p = 0.44) or disease-free survival (HR = 0.74, p = 0.11). Protein interaction analysis revealed strong interactions between PALB2 and major DNA repair proteins including BRCA1, BRCA2, RAD51, RAD51C, FANCD2, and BRIP1. Functional enrichment analysis showed limited significant pathway enrichment, with only marginal transcription factor motif enrichment observed. Mutational analysis demonstrated diverse genomic alterations including missense mutations, truncating mutations, copy number gains, and shallow deletions. ConclusionThe findings support the biological relevance of PALB2 in breast cancer through its elevated expression and strong connectivity within DNA repair pathways. However, PALB2 expression alone does not appear to serve as an independent prognostic indicator. Further studies integrating genomic, transcriptomic, and clinical parameters are required to clarify its role in breast cancer progression and therapeutic response.